Pune, India -- (SBWire) -- 03/08/2019 --The Global Human Microbiome Market accounted to US$ 257.30 Mn in 2017 and is expected to grow at a CAGR of 21.8% during the forecast period 2018 - 2025, to account to US$ 1,197.08 Mn by 2025. North America is the largest geographic market and it is expected to be the largest revenue generator during the forecast period. North American market is driven by the factors such as, increasing focus on development of microbiome therapeutics and conferences in this region
Market Insights: Increasing Incidence of Lifestyle Diseases
Over the past few decades, human microbiome is related to lifestyle diseases like cancer, diabetes, obesity, depression and many others. Changes in lifestyles and societal norms influence the microbiome at each stage of life. Altering the human microbiome can help in eliminating such lifestyle diseases. As per World health organization in 2016, 13% of the world population (adults) were obese. According to the "The New Era of Treatment for Obesity and Metabolic Disorders: Evidence and Expectations for Gut Microbiome Transplantation" published in 2016, microbes residing in the human gastrointestinal tract act as an endocrine organ, whose composition and functionality contribute to the development of obesity. Therefore, fecal/gut microbiome transplantation (GMT), which involves the transfer of feces from a healthy donor to the patient, is a potential treatment for obesity.
The major players operating in the human microbiome market include Enterome, MicroBiome Therapeutics, LLC, Rebiotix Inc, Yakult Honsha Co., Ltd., Osel Inc., Vedanta Biosciences, Inc., Metabiomics Corporate, Synthetic Biologics, Inc., DuPont, and BiomX Ltd.
Download Sample PDF Brochure of this report at https://www.theinsightpartners.com/sample/TIPBT00002233/
Growing Technological Advancements in Metagenomics and Next-generation Sequencing:
Technological advancements in metagenomics and next-generation sequencing have made microbiome-based testing easier and cheaper, and have led to rapid analysis of the genomic content of microorganisms from human sample. This has bolstered the development process for microbiome-based diagnostics. Gastrointestinal and metabolic disorders are likely to capture the leading share of the diagnostics market in 2018 owing to rise in interest of companies toward developing an easy analysis platform for gut health-based disorders, such as irritable bowel syndrome and Crohn's disease. Although cancer is likely to capture a minor share of the market in 2018, much lower than gut health and metabolic disorders, it is a niche operating area for the company involved in developing a diagnostic test for detecting cancer. For instance, Metabiomics is developing molecular diagnostics for detecting markers of colorectal cancer. Existing tests for colorectal cancer rely on invasive colonoscopies; and thus, the non-invasive test developed by Metabiomics (which uses a stool sample to evaluate patient's gut microbiome) will be a unique opportunity for the company to excel in a market having huge unmet needs.
Product Insights:
The global human microbiome market by product was led by probiotics segment. In 2017, the probiotics segment held a largest market share of 24.7% of the human microbiome market, by product. The probiotics segment is expected to dominate the market in 2025, due to increasing health concerns, growing awareness regarding the relation of nutrition, diet, and health, and increasing probiotics market penetration in dairy and other food and beverages industry is expected to favor the overall demand.
Disease Insights:
The human microbiome market by disease was segmented into diabetes, cancer, autoimmune disorders, obesity, mental disorders and other diseases. The obesity segment held the largest share of the market, by disease. The segment is also likely to dominate in the forecast period, due to increase in the cases of obesity, caused due to various factors such as, lifestyle changes, sedentary lifestyle as well as unhealthy eating habits.
Application Insights:
The human microbiome market by application was segmented into diagnostics and therapeutics. The therapeutics segment held the largest share of the market, by application. The segment is also anticipated to grow at a steady rate during the forecast period, owing to the increase in digestive problems, increase in the drug-related side effects.
Strategic Insights:
Expansion and patent and license approvals were observed as the most adopted strategy in global human microbiome industry. Few of the recent expansions and license as well as patent approvals made by the players are listed below:
2018: In April, 2018, MicroBiome Therapeutics, LLC (MBT), announced the launch of BiomeBliss, a patented, first-in-class prebiotic dietary supplement specifically developed to support a healthy gastrointestinal (GI) microbiome.
2017: In June, 2017, Guangzhou Yakult Co., Ltd. in Guangdong Province, China, would start constructing the Foshan Plant in Foshan, Guangdong Province in July 2017 for production of the Yakult and Yakult Light.
Increasing incidence of lifestyle diseases is expected to drive the growth of the market. However, strict government guidelines is expected to hamper the growth of the market. Over the past few decades, human microbiome is related to lifestyle diseases like cancer, diabetes, obesity, depression and many others. Changes in lifestyles and societal norms influence the microbiome at each stage of life. Altering the human microbiome can help in eliminating such lifestyle diseases. As per World health organization in 2016, 13% of the world population (adults) were obese.
According to the "The New Era of Treatment for Obesity and Metabolic Disorders: Evidence and Expectations for Gut Microbiome Transplantation" published in 2016, microbes residing in the human gastrointestinal tract act as an endocrine organ, whose composition and functionality contribute to the development of obesity. Also, according to the World Health Organization in 2018, cancer was the second leading cause of death across the globe, and is responsible for an estimated 9.6 million deaths in 2018. Furthermore, the American Cancer Society estimated that in 2018, 1,735,350 new cancer cases were diagnosed. Thus, the increasing incidence of lifestyle diseases is expected to fuel the growth of human microbiome market over the forecast years.
The strict government guidelines are intended to hamper the market to an extent. The advancements in science and technology made the scientists excited about the potential and potency of fecal matter and the microbes in it. The cell-based therapies found a novel paradigm in drug development, a regulatory framework that reports safety and bio containment issues should be established to minimize adverse events and environmental release of engineered organisms. Government agencies should offer conceptual frameworks for efficient and sensible regulatory schemes, and ways for construing intellectual property that provide appropriate incentives for private investment while protecting the public good. The FDA regulations on these procedures, however, keep them out of reach for most patients. The use of technology employing knowledge of the human microbiome is getting started and not yet widely applied. However, it is important to consider the ethical issues early, so as to avoid at least those pitfalls that can be identified at the initial stage rather than waiting for a disaster to happen and then trying to cobble together hasty responses. Thus, the risk factors associated with human microbiome are expected to confine the growth of global human microbiome market over the forecast years.
Directly Purchase/Place an Order for a copy of this research report at https://www.theinsightpartners.com/buy/TIPBT00002233/
The increasing incidence of lifestyle diseases are expected to fuel the market growth during the forecast period. As per World health organization in 2016, 13% of the world population (adults) were obese. According to the "The New Era of Treatment for Obesity and Metabolic Disorders: Evidence and Expectations for Gut Microbiome Transplantation" published in 2016, microbes residing in the human gastrointestinal tract act as an endocrine organ, whose composition and functionality contribute to the development of obesity. However, the strict government guidelines is the major concern in the human microbiome market. The strict government guidelines are intended to hamper the market to an extent. The advancements in science and technology made the scientists excited about the potential and potency of fecal matter and the microbes in it.
The cell-based therapies found a novel paradigm in drug development, a regulatory framework that reports safety and bio containment issues should be established to minimize adverse events and environmental release of engineered organisms. In recent years, for drug discovery the microbiota plays an important role in the efficacy of therapeutic compounds. There is a new phenomenon in the globe. It is the human gut microbiome and the role it may play in the future of human health. Recently various reports have indicated that the human gut microbiome may be implicated in health conditions such as obesity, metabolism, diabetes, immunity and autism.
Key Benefits of Buying this Research Study:
1. Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the global Human Microbiome market
2. Highlights key business priorities in order to assist companies to realign their business strategies
3. The key findings and recommendations highlight crucial progressive industry trends in the Human Microbiome market, thereby allowing players across the value chain to develop effective long term strategies
4. Develop/modify business expansion plans by using substantial growth offering developed and emerging markets
5. Scrutinize in-depth global market trends and outlook coupled with the factors driving the market, as well as those hindering it
6. Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing and distribution
7. Examine the political, economic, social and technology impact of the five regions namely: North America, Europe, Asia Pacific, Middle East & Africa and South America.
About The Insight Partners
The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We are a specialist in Technology, Healthcare, Manufacturing, Automotive and Defense.
